Life Science and Biotech CEO stories – Détails, épisodes et analyse

Tune in for this insightful podcast with David Weinstock, the Vice President of Discovery Oncology at Merck, to find out what pharma investors really think when they are interviewing startups looking for funding.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Our guest today is another Atlanta luminary, Dr. Marvin Whiteley, the founder and CSO of SynthBiome, Inc. Deaths are expected to increase over the next 20-30 years due to antibiotic resistant infections.

It’s common for people to go into the hospital for something innocuous, get an infection, and find that the bacterium doesn’t respond to antibiotic. There are strains infecting people outside of clinical settings, as well. As there are millions of deaths caused by this each year, the alarm bells are starting to go off because we are not developing a lot of new antibiotics.

How can this trend be stopped?  

Disclaimers

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Today I am really excited to have Charles Gellman, CEO of HiDO Health. HiDO is a company that is focused on using artificial intelligence to help patients manage their medications for chronic disease. Each year, almost 250,000 in America die as a result of medical errors associated with lack of adherence to a prescription schedule, making it the third largest cause of death in the US.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Our guest today is Dr. Amy Baxter, the CEO of Pain Care Labs, a company dedicated to using mechanical platforms such as vibrating devices to alleviate fear and pain associated with needles as well as reducing muscular skeletal pain in adults.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations.  Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Today we are joined by Charles DeCoster, CEO, and Tony Watson, COO, of Xenocor, a company that is revolutionizing laparoscopic surgery with a new scope they call Saberscope. This device was designed to be less expensive, more effective at providing the surgeon with available light, and safer for the patient.

Laparoscopic surgery was invented in the 1980’s and the technology platform is now 30 years old. It has not changed dramatically since then. The single use model eliminates a lot of the frustrations. You open up the package, you plug it in. That’s the whole workflow. A reusable scope’s workflow, from the time it gets opened in the OR to the time it gets back to the OR to be used again, is quite onerous. By making it single use, they are reducing waste and simplifying the process.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

This episode we’re doing something different. We’re visiting some of the most compelling stories and CEOs of our earlier editions, to update their journeys. I wanted to do this for two reasons.

·       The people in this industry are some of the grittiest, most determined, and most philanthropic, in terms of their commitment to their science and patients, people that I have ever known.

·       By following these individual journeys I hope somehow to demonstrate the incredibly fast pace of innovations taking place.

Our guests are:

·       Abdulkader Rahmo, PhD

·       Torrey Smith

·       Dr. Nikhil Shah

·       Tan Rasab

·       Jacob Glanville

Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Recently on the Biotech and Life Science CEO’s podcast, we’ve been talking about the speed at which change is occurring in the life sciences. And nowhere is that clearer than in the field of mRNA. By now everyone must know that the COVID vaccines were created literally days after the genome of the virus had been sequenced. But I don’t think we’ve still processed what that really means.

Our guest today is Dr. Pooja Tiwari, the founder of Arnav Biotech, dedicated to the design and manufacture of both custom and cataloged mRNA for use in therapeutic vaccine, diagnostic, and even agricultural applications.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations.  Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

In this podcast, we are joined by historian Dr. Nicolas Hoffmann who recounts a slew of quirky Civil War medicine stories that will have you rolling in laughter.

Let’s go!

Over the last few months of this podcast, we’ve had the opportunity to learn about tiny pill-sized endoscopes that can be swallowed and controlled on their path through the digestive tract by the healthcare provider.

We’ve heard about the prospects for a universal flu vaccine whose chemistry would be consistent from one year to the next whose efficacy could be better than 90%.

A smaller, less expensive tool for targeted genetic sequencing.

And many other amazing innovations.

In other words, things are happening really fast.

But today, our thought is a little bit different. We’re going to try to juxtapose history with what is currently happening in an effort to demonstrate exactly what those changes are and how fast those changes are going to be.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations.  Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative.

Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Today we are going to discuss advancements in improving the efficiency of those clinical trials. Our guest is Ian Strug who is the co-founder and Chief Revenue Officer at Virgo Surgical Video Solutions. Virgo provides cloud video capture, management, and artificial intelligence analysis for endoscopic medicine.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations.  Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative.

Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

There are currently the following bottlenecks to the manufacturing of biologics, or medications such as gene therapies, vaccines, and etc. that are derived from organic sources such as plants or animals.

The obstacles to large scale biologic dissemination are:

1. Delivering the biologic to the target

2. Manufacturing, producing it at scale

3. Selecting patients for clinical trials in a way that enhances the efficacy of the trial

These challenges have, up until now, made biologics more expensive to administer and that higher price tag can make access limited to the population at large. Significant improvement will come when those bottlenecks release.

Are we on the verge of a breakthrough?

We are pleased to interview Dr. Alexander Koglin, co-founder and CSO of Nature’s Toolbox, in this month’s show who will discuss the progress that is being made in biomanufacturing and what it may mean for society.

The information contained in this website and podcast are purely informational and not considered

investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart

from his role as an investment advisor representative. Nothing contained herein may be construed as a

recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial

affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no

representation that the information conveyed in this material is accurate and is under no obligation to

update this information as changes occur.